Oshitani H, Takeda H, Nihei T, Kobayashi H
Jpn J Antibiot. 1984 Sep;37(9):1603-6.
A study was carried out with the aminoglycoside antibiotic micronomicin (MCR) to determine its clinical efficacy in respiratory infections on the one hand and its serum levels on the other. MCR was administered in single dose of 60 mg twice daily by intravenous drip infusion over 1 hour to 5 patients with infections aggravation of chronic bronchitis and 3 with pneumonia. Of the total of 8 patients treated, 3 had remarkable and 4 had good responses with a response rate of 87.5%, while 1 has no benefit. Adverse effects on the clinical picture or on laboratory test results were not observed. The peak serum concentration of MCR after a 1.5 hours drip infusion of 90 mg was 7.74 micrograms/ml. In view of the risk of adverse effects, the serum concentration lay on appropriate levels. It is expected therefore that the intravenous drip infusion of MCR will be of particular interest in the treatment of relapse of chronic bronchitis and pneumonia.
开展了一项关于氨基糖苷类抗生素小诺米星（MCR）的研究，一方面确定其在呼吸道感染中的临床疗效，另一方面测定其血清水平。对5例慢性支气管炎感染加重患者和3例肺炎患者，以每日两次、单次剂量60mg、静脉滴注1小时的方式给予小诺米星。在总共8例接受治疗的患者中，3例疗效显著，4例效果良好，有效率为87.5%，而1例无疗效。未观察到对临床症状或实验室检查结果的不良反应。在静脉滴注90mg、1.5小时后，小诺米星的血清峰值浓度为7.74微克/毫升。鉴于存在不良反应风险，血清浓度处于适当水平。因此，预计静脉滴注小诺米星在治疗慢性支气管炎和肺炎复发方面将具有特殊意义。
